Jennifer Aldrink

Professor of Clinical Surgery and Pediatrics

Nationwide Children's Hospital
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jennifer Aldrink is a Professor of Clinical Surgery and Pediatrics at Nationwide Children's Hospital in the United States. Her research focuses on pediatric surgical oncology, with recent publications exploring transfusion characteristics in hepatoblastoma, outcomes of stereotactic body radiation therapy for metastatic osteosarcoma, and innovations in minimally invasive surgical approaches. Additionally, she examines the critical aspects of oncofertility care and pediatric trauma readiness, contributing to advancements in the care of children globally.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Introduction The purpose of this study is to examine the outcomes in children with anaplastic bilateral Wilms tumor (BWT) from study AREN0534 in order to define potential prognostic factors and areas to target in future clinical trials. Methods Demographic and clinical data from AREN0534 study patients with anaplasia (focal anaplasia [FA], or diffuse anaplasia [DA]) were compared. Event‐free survival (EFS) and overall survival (OS) were reported using Kaplan–Meier estimation with 95% confidence bands, and differences in outcomes between FA and DA compared using log‐rank tests. The impact of margin status was analyzed. Results Twenty‐seven children who enrolled on AREN0534 had evidence of anaplasia (17 DA, 10 FA) in at least one kidney and were included in this analysis. Twenty‐six (96%) had BWT. Nineteen percent had anaplastic histology in both kidneys (four of 17 DA, and one of 10 FA). Forty‐six percent with BWT had bilateral nephron‐sparing surgery (NSS); one child who went off protocol therapy, eventually required bilateral completion nephrectomies. Median follow‐up for EFS and OS was 8.6 and 8.7 years from enrollment. Four‐ and 8‐year EFS was 53% [95% confidence interval (CI): 34%–83%] for DA; 4‐year EFS was 80% [95% CI: 59%–100%], and 8‐year EFS 70% [95% CI: 47%–100%] for FA. Three out of 10 children with FA and eight out of 17 children with DA had events. EFS did not differ statistically by margin status ( p = .79; HR = 0.88). Among the six children who died (five DA, one FA), all experienced prior relapse or progression within 18 months. Conclusion Events in children with DA/FA in the setting of BWT occurred early. Caution should be taken about interpreting the impact of margin status outcomes in the context of contemporary multimodal therapy. Future targeted investigations in children with BWT and DA/FA are needed.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (14)

Daniel Benedetti

Vanderbilt University Medical Center

UNITED STATES
View details

Timothy B. Lautz

-

UNITED STATES
View details

Audra Reiter

McGaw Medical Center of Northwestern University

UNITED STATES
View details

Emily Christison-Lagay

Yale University

UNITED STATES
View details

Erin Brown

University of California, Davis

UNITED STATES
View details

Afif Kulaylat

Assistant Professor of Surgery and Pediatrics

Penn State Health Children's Hospital

UNITED STATES
View details

Zachary Kastenberg

University of Utah

UNITED STATES
View details

Michela Carter

University of Cincinnati

UNITED STATES
View details

Jack Brzezinski

Associate Professor

University of Washington

UNITED STATES
View details

Robin Petroze

University of Michigan

UNITED STATES
View details

Mary Fallat

University of Louisville

UNITED STATES
View details

Jiancong Liang

Vanderbilt University Medical Center

UNITED STATES
View details

Peter F. Ehrlich

-

UNITED STATES
View details

James I. Geller

-

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.